NCT07064538

Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

A Mixed-Methods Open-Label Trial Evaluating the Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Mackay Memorial Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of Neuralli® MP in improving participant-defined outcomes in adults with autistic traits.

Detailed description

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder characterized by pervasive difficulties since early childhood across reciprocal social communication and restricted, repetitive interests and behaviors. Although early ASD research focused primarily on children, there is increasing recognition that ASD is a lifelong neurodevelopmental disorder. However, although health and education services for children with ASD are relatively well established, service provision for adults with ASD is in its infancy. There is a lack of health services research for adults with ASD, including identification of comorbid health difficulties, rigorous treatment trials (pharmacological and psychological), development of new pharmacotherapies, investigation of transition and aging across the lifespan, and consideration of sex differences and the views of people with ASD. The health services research for adults with ASD is urgently warranted. In particular, research is required to better understand the needs of adults with ASD, including health, aging, service development, transition, treatment options across the lifespan, sex, and the views of people with ASD. Lactiplantibacillus plantarum PS128 (PS128), showed ameliorative effects on depression- and anxiety-like behaviors in different mouse models. When administered to children with ASD, PS128 was shown to improve anxiety, rule-breaking behaviors, hyperactivity/impulsivity, social function, inflammation index, and autonomic function. PS128 supplementation has also been shown to improve depressive symptoms and sleep quality for adults with self-reported insomnia, as well as cortisol levels and anxiety. However, even for this well-studied probiotic, its specific effects on broader aspects of ASD, such as core symptoms, cognition, attention, and sleep have not been systematically investigated. Therefore, this study is designed not only to examine the effects of Neuralli® MP (PS128) but, more importantly, to explore the wider health and support needs of adults with autistic traits. By doing so, this study aims to assess how PS128 may contribute to improving their overall quality of life and address a range of symptoms.

Conditions

• ASD
• Autism
• Autistic Disorders Spectrum

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Neuralli® MP	Neuralli® MP containing 60 billion CFU (administered as two capsules per day)

Timeline

• Start date: 2025-08-19
• Primary completion: 2026-06-30
• Completion: 2026-08-31
• First posted: 2025-07-14
• Last updated: 2025-08-24

Locations

1 site across 1 country: Taiwan